Abstract YO12
Case summary
Case report : Hepatic EBV-associated Smooth Muscle Tumor (EBV-SMT)
A 51-year-old Thai man with history of HIV infection and chronic HBV hepatitis was sent to Vajira Hospital to evaluate liver lesions. He once had had pulmonary tuberculosis that was properly treated. Two years ago, the liver masses had been first identified on ultrasonography obtained routinely for HCC surveillance. At that moment, he was asymptomatic. His blood counts and blood chemistries including serum AFP were all unremarkable.
The triple-phase CT scan demonstrated two peripheral arterial enhancing masses with progressively enhanced on porto-venous and delayed phases, measured 5.7x4.7 cm and 4.2x3.4cm at segment IVa and IVb, respectively. Another enhancing nodule at porto-venous phase with decreased enhancement at delayed phase was found at segment V. Hepatic hemangioma had been considered and he had been advised to be closely observed, until three months ago, the repeated CT scan showed increasing size of the liver lesion at segment IVa to 6.0x4.7x5.1 cm, the rests were still stable in size.
At Vajira Hospital, he looked healthy. Physical examination was unrevealing. His blood count is normal. His blood chemistries were remarkable for mild elevation of ALT (194 U/L) (normal level, 46-116 U/L). His latest CD4 count and HIV viral load collected on 27/2/60 were 244/mm3 and less than 40 copies/mL, respectively. He was taking TDF/FTC/EFV.
MRI of upper abdomen revealed three progressively heterogeneously enhancing liver masses at segment at segment IVa, IVb, and V. The largest one was about 7.0x4.5x5.2 cm. The masses were in proximity of the left and middle hepatic veins. Percutaneous biopsy under CT guidance was done. It reported atypical spindle cell proliferation. IHC staining were positive for SMA and EBER, but negative for CD31, CD34, ERG, FLI-1, HHV-8, and Desmin. Thereby, EBV-SMT was diagnosed.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
237P - PARP inhibitor in platinum resistant ovarian cancer: Single center real world experience
Presenter: Saphalta Baghmar
Session: Poster display session
Resources:
Abstract
238P - Laparoscopic cytoreduction in low disease burden, advanced-stage ovarian cancers: Experience from a tertiary cancer center
Presenter: Vikas Gupta
Session: Poster display session
Resources:
Abstract
239P - Impact of counseling on patient reported sexual adjustment following chemoradiation and brachytherapy for cervical cancer
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
240P - Morbidity and mortality of cervical cancer in the Republic of Kazakhstan
Presenter: Almagul Zhabagina
Session: Poster display session
Resources:
Abstract
241P - Impact of genomic alterations and HPV genotypes on clinical outcomes of Japanese patients with locally advanced cervical cancer
Presenter: Ikumi Kuno
Session: Poster display session
Resources:
Abstract
242P - Impact of combined interstitial and intracavitary brachytherapy in locally advanced cervical cancer: A survival and toxicity profile assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
243P - Cervical cancer screening in sub-urban area of Banten and factor associated with uptake of screening
Presenter: Prio Wibisono
Session: Poster display session
Resources:
Abstract
245P - Factors influencing adherence to cryotherapy following positive VIA result as cervical cancer prevention in Temanggung, Central Java, Indonesia
Presenter: Herindita Puspitaningtyas
Session: Poster display session
Resources:
Abstract
246P - The main of reasons of advanced stage cervical cancer in Uzbekistan
Presenter: Zakhirova Nargiza
Session: Poster display session
Resources:
Abstract
247P - Role of ADC values in assessing response after chemoradiotherapy in cervix cancer and in identifying residual disease
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract